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Abstract
Background: Wig-1 is a transcription factor regulated by p53 that can interact with hnRNP A2/B1, RNA Helicase A, and
dsRNAs, which plays an important role in RNA and protein stabilization. in vitro studies have shown that wig-1 binds p53
mRNA and stabilizes it by protecting it from deadenylation. Furthermore, p53 has been implicated as a causal factor in
neurodegenerative diseases based in part on its selective regulatory function on gene expression, including genes which, in
turn, also possess regulatory functions on gene expression. In this study we focused on the wig-1 transcription factor as a
downstream p53 regulated gene and characterized the effects of wig-1 down regulation on gene expression in mouse liver
and brain.
Methods and Results: Antisense oligonucleotides (ASOs) were identified that specifically target mouse wig-1 mRNA and
produce a dose-dependent reduction in wig-1 mRNA levels in cell culture. These wig-1 ASOs produced marked reductions
in wig-1 levels in liver following intraperitoneal administration and in brain tissue following ASO administration through a
single striatal bolus injection in FVB and BACHD mice. Wig-1 suppression was well tolerated and resulted in the reduction of
mutant Htt protein levels in BACHD mouse brain but had no effect on normal Htt protein levels nor p53 mRNA or protein
levels. Expression microarray analysis was employed to determine the effects of wig-1 suppression on genome-wide
expression in mouse liver and brain. Reduction of wig-1 caused both down regulation and up regulation of several genes,
and a number of wig-1 regulated genes were identified that potentially links wig-1 various signaling pathways and diseases.
Conclusion: ntisense oligonucleotides can effectively reduce wig-1 levels in mouse liver and brain, which results in specific
changes in gene expression for pathways relevant to both the nervous system and cancer.
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Introduction
wig-1 is a p53-regulated gene (WT p53 induced gene 1; also
known as PAG608 and ZMAT3) that was originally identified in a
mouse cell line using a PCR-based differential display technique to
find mRNAs induced by wild type p53 [1,2]. The wig-1 gene
encodes a C2H2-type zinc finger protein that localizes mainly to
the nucleus [3,4]. The wig-1 structural features are shared with a
small group of proteins, such as JAZ, that can positively regulate
p53 transcriptional activity in a positive feedback manner [5,6]. A
rat homolog of wig-1, PAG608, was independently identified by
Israeli et al. [2] and human wig-1 has also been cloned and
characterized [3]. Mouse wig-1 is highly homologous to the rat
and human orthologs, and shares 97.9% and 87% amino acid
sequence identity, respectively. Rat wig-1 (PAG608) has weak pro-
apoptotic activity when over-expressed in human tumor cells and
human wig-1 can suppress cell growth by 25–30% in a colony
formation assay [2,3].
wig-1 has also been shown to interact with heterogeneous
nuclear ribonucleoprotein (hnRNP) A2/B1, RNA Helicase A
(RHA), and dsRNA [4,7,8]. A relationship between wig-1 and p53
was also concluded in studies in which wig-1 was suppressed by
siRNA in vitro. It was shown that wig-1 binds to p53 mRNA in
vitro and stabilizes it by protecting it from deadenylation. It was
suggested that this effect is mediated by the U-rich region in the 39
UTR of p53 mRNA [9]. Because p53 is involved in regulating cell
death, it has the potential to play a significant role in the
progression of neurodegenerative diseases including Huntington
Disease (HD) where it has been found to affect phenotype in
mouse models of HD [10]. Furthermore, a genetic interaction
between the murine homologue of huntingtin (htt) and p53 has also
been reported to cause significant reductions in the severity of the
HD phenotype in mice [11]. Moreover, recent in vitro and animal
studies have shown that activation of p53 can promote huntingtin
transcription and up-regulation of wild-type HTT protein,
suggesting that p53 and htt might interact functionally, and that
changes in p53 status may alter the HTT levels and, presumably,
the HD phenotype [12].
The role of p53 in HD pathogenesis will likely involve different
pathways, and it seems that targets of p53 activity might be
responsible for different aspects of p53-related effects within
neurodegenerative pathways. In this study we decided to focus on
wig-1 as a potential downstream target of p53 in neurodegener-
ative diseases by identifying genes that are potentially under
regulation by wig-1. Microarray analysis was performed on the
striatum of the HD mouse model, BACHD, treated locally with or
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7without wig-1 antisense oligonucleotides (ASOs), and on the liver
following systemic treatment with wig-1 ASOs [13,14,15]. Our
studies identify a number of neuronal and non-neuronal genes that
are affected by wig-1 expression in mouse brain and liver.
Furthermore, genes found to be impacted by wig-1 suppression
have been implicated in a wide range of critical pathways involved
in neuronal function such as brain development and axon
guidance, cancer, and mitochondrial function.
Results
Identification and characterization of a wig-1 antisense
inhibitor in vitro and in vivo
To study the effects of wig-1 on htt and p53, we designed antisense
oligonucleotides to specifically target mouse wig-1 mRNA. These
chimeric ASOs contain ribonuclease H-sensitive stretches of 29-deoxy
residues flanked on both sides with a stretch of 29-O-(2-methoxyethyl-
ethyl) modifications, which increases RNA binding affinity and
confers nuclease resistance. The central 29-deoxy domain produces a
substrate for endogenous RNase H enzymes once hybridized to the
complementary target RNA, resulting in cleavage of the target RNA,
thereby causing lowering of target protein levels [16] (Figure 1A). A
series of ASOs were designed to bind within the coding region of the
wig-1 mRNA sequence. Rapid-throughput screens were performed
in the immortalized mouse brain endothelial cell line, bEND. Cells
were transfected with ASOs, and harvested after 24 hours. The
reduction of wig-1 expression was analyzed with real-time quantita-
tive RT-PCR. Based on relative reduction in wig-1 mRNA levels, 4
ASOs were selected and further characterized in a dose-response
screen. Wig-1 mRNA levels were significantly decreased in a dose-
dependent manner with 90–95% reduction in wig-1 mRNA levels
observed at a concentration of 45 nM (Figure 1B). These ASOs were
further characterized in animals.
In vivo activity of wig-1 ASOs was characterized following
intraperitoneal (IP) administration at 50 mg/kg or saline, twice a
week for 4 weeks in BALB/c mice. Animals were euthanized 48 hours
following the last dose. Serum transaminases,organ weights and organ
histopathology were performed as a measure of overall tolerability.
Liver samples were analyzed for changes in wig-1 mRNA levels and
compared to saline treatment. All four ASOs reduced wig-1 mRNA
levels by approximately 80% and ASO treatment was well tolerated
(Figure 1C). One wig-1 ASO (ASO3) was selected for further studies.
Characterization of wig-1 ASO activity in mouse brain
Whole brain extracts of mice show relatively high expression
levels of wig-1. To characterize the effects and the duration of
Figure 1. Mouse Wig-1 ASOs specifically reduce wig-1 mRNA levels in vitro and in vivo. A) oligonucleotides were 20 nucleotides in length
and chemically modified with phosphorothioate in the backbone and 29-O-methoxyethyl (MOE) on the wings with a central deoxy gap (‘‘5-10-5’’
design). B) b.END cells were transfected with indicated concentration of wig-1 ASOs. RNA was extracted 24 hours after transfection and analyzed by
RT-PCR to determine wig-1 mRNA levels. C) Male BALB/c mice were injected intraperitoneally with 4 different wig-1 ASOs at 100 mg/kg body weight
per week or with saline for 4 weeks. Total RNA was prepared from liver, and used for real-time quantitative RT-PCR analysis to evaluate wig-1 mRNA
levels. Data are expressed as means 6 SEM (n=4, ***p#0.01).
doi:10.1371/journal.pone.0029429.g001
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ASO to FVB mice (the background strain for BACHD) (8-weeks-
old) by a single bolus injection into the right striatum at 25, 50, and
75 mg and determined the effects on wig-1 mRNA and protein
levels in brain tissue after one, two, three and four weeks post
injection (Figure 2). Immunohistochemistry using an antibody that
reacts with ASO confirmed ASO distribution to different regions
of the brain as well as ASO uptake by different cell types
(Figure 2A). Wig-1 ASO was taken up by both neuronal and glial
cells, which is consistent with previous studies on ASO intrathecal
administration in rats [17]. Immunostaining was present in
sections of the brain, adjacent to the injection site as well as other
regions, but staining decreased in intensity in a gradient as the
distance increased from the injection site (Figure 2A). Hematoxylin
and eosin staining of brain sections did not show any noticeable
morphological abnormalities following ASO injection nor did any
animals display abnormal behavior (data not shown). The
magnitude of reduction of wig-1 mRNA levels was dependent
on the dose of injected ASO with approximately 40% wig-1
mRNA reduction observed at 25 mg ASO and maximal (,80%)
reduction observed at 50 mg ASO. Furthermore, the duration of
action of the wig-1 ASO lasted between 3 and 4 weeks following a
single 75 mg dose (Figure 2B).
Reduction in wig-1 levels promotes reduction in mutant
HTT levels but fails to decrease p53 levels in vivo
To determine the effects of wig-1 knockdown on htt expression,
wig-1 ASO was administered as a single striatal injection (75 mg) in
5 month old BACHD mice, a model of Huntington’s disease, and
compared with PBS or a control oligonucleotide. BACHD mice
express full length human mutant htt with 97 glutamine repeats
under the control of endogenous htt regulatory elements. These
mice exhibit progressive motor deficits, neuronal synaptic
dysfunction, and late-onset selective neuropathology, which
include significant cortical and striatal atrophy and neuronal
degeneration. Animals were euthanized one or three weeks
following the ASO administration, and wig-1 mRNA and protein
levels were determined. Immunohistochemistry was used to
confirm ASO distribution and to assess morphological changes
in brain sections. Wig-1 mRNA levels were significantly reduced
(,70%) at both one and three weeks following ASO treatment
whereas treatment with control oligonucleotide had no effect on
wig-1 mRNA levels (Figure 3A). Furthermore, reduction in wig-1
protein levels was also observed in wig-1 ASO-treated samples
with reductions comparable to the observed reductions in mRNA
levels (Figure 3B). Interestingly, treatment with wig-1 ASO
resulted in small (,40%) but significant lowering of mutant htt
Figure 2. Dose-dependent reduction of wig-1 mRNA levels in mice brain following striatal bolus administration. A) Distribution of
Wig-1 ASO was confirmed by staining with an antibody that recognizes oligonucleotides. At higher magnification ASO is visible in variuos cells
including neurons, astrocytes. B) Male FVB mice received 75 mg single bolus injection of wig-1 ASO, or PBS in striatum. Animals were sacrificed after
one, two, three, or four weeks. Striatum were harvested and total RNA was prepared from these sections, and used for real-time quantitative RT-PCR
analysis to evaluate levels of wig-1 mRNA. Histological examination with hemotoxylin and eosin (H & E) staining did not show any remarkable
abnormality in the brain of treated animals compare with control (data not shown). Data are expressed as means 6 SEM (n=4;**p#0.05; ***p#0.01).
doi:10.1371/journal.pone.0029429.g002
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protein were not significantly changed following wig-1 ASO
treatment (Figure 3B).
The effects of wig-1 ASO treatment on p53 mRNA and protein
levels was examined next in BACHD and FVB brain, and in
BALB/c liver. Surprisingly, no reduction in p53 levels was
observed in wig-1 ASO treated animals despite marked reduction
in wig-1 levels. In fact, there was a slight trend for increased levels
of p53 mRNA in BACHD and FVB striatum and p53 protein
levels in FVB striatum in animals treated with wig-1 ASO
(Figure 4A & B). Furthermore, whole cell lysate of BALB/c liver
samples did not show any increase or decrease in p53 levels
Figure 3. Effects of wig-1 ASO intrastriatal treatment on wig-1 and HTT levels in BACHD striatum. 5-month-old male BACHD mice
received 75 mg single bolus injection of wig-1 ASO, PBS, or control ASO in striatum. Animals were sacrificed after one, or three weeks. A) Striatum was
harvested and total RNA was prepared from these sections, and used for real-time quantitative RT-PCR analysis to evaluate the expression of wig-1
mRNA. B) Tissue homogenates were prepared from striatum and used for analysis of Wig-1 and HTT protein levels. Data are expressed as means 6
SEM (n=4;**p#0.05; ***p#0.01). Letters A1–A4, B1–B4, D1–D4 refer to individual animals.
doi:10.1371/journal.pone.0029429.g003
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were extracted from BACHD striatum of mice treated with 75 mg of wig-1 ASO, PBS, or control ASO. B) p53 mRNA and protein levels in mouse FVB
striatum following ASO injection with increasing doses of wig-1 ASO, and C) Effects of wig-1 ASO treatment on p53 mRNA and protein levels in
mouse liver. Data are expressed as means 6 SEM (n=4).
doi:10.1371/journal.pone.0029429.g004
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suggest that wig-1 does not influence p53 mRNA or protein levels
directly in mouse striatum and liver.
Expression profile analysis of brain samples treated with
wig-1 ASO
Gene array expression analysis was performed on BACHD mice
treated with wig-1 ASO versus vehicle treated animals in order to gain
insight into putative pathways affected by wig-1 suppression. Gene
expression profiles of BACHD striatum were obtained in mice through
whole genome microarray analysis. Genes with significant changes in
expression following wig-1 ASO treatment were identified todetermine
potential gene pathways under control of wig-1 using, Ingenuity
TM
Pathway Analysis software (Ingenuity Systems, CA, USA).
To improve the probability of successfully identifying novel
pathways regulated by wig-1, a large number of genes displaying
altered expression following wig-1 ASO treatment was obtained to
support gene network analysis. We filtered on statistically
significant genes (FDR cutoff 0.1) having 2log10(p-values).=3.0
and absolute fold-changes .=1.5. This filtering approach created
a probe list of 260 genes that exhibited altered expression upon
wig-1 ASO treatment. A hierarchical cluster analysis [18] of the
log2 intensity profiles of the 260 genes is shown as a heatmap in
Figure 5. This heatmap shows that both up-regulation and down-
regulation of genes occurs in BACHD mouse striatum when
treated with wig-1 ASO, with a larger portion of genes showing
up-regulation. In fact, using the selection criteria described, 204
genes were found to be up regulated and 56 genes down regulated
following wig-1 ASO treatment. Many genes which were
significantly down-regulated are predicted to play a role in
nervous system development and function, psychological disorders
and cell-cycle control (table 1, and Figure S2). Furthermore,
analysis of the up-regulated genes identified genes that are
Figure 5. Heatmap of the log2 normalized intensities of the significantly differentially expressed 260 gene probes on the array. The
columns represent the PBS, ASO treated, and negative control samples and the rows represent the 260 differentially expressed gene probes on the
array. The heatmap shows that the majority of the differentially expressed genes show mostly upregulation after ASO treatment. This is shown by the
transition of probe intensities to higher values relative to the PBS and negative control samples for the 260 gene probes. The dendrogram on the left
of the heatmap shows the clustering of genes having similar profiles across samples. The dendrogram on top of the heatmap shows the clustering of
the samples. The PBS and negative control samples clustered together whereas the ASO treated samples clustered separately.
doi:10.1371/journal.pone.0029429.g005
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signaling (table 2, and Figure S3).
PCR and western blot confirmation
RT-PCR confirmation of microarray results was performed on
a subset of genes identified as being down regulated following wig-
1 ASO treatment. Specifically, five genes (PKCe, AUTS2,
ROBO2, PLEKHA5, and IMMPL2) were selected for confirma-
tion. Consistent with microarray results, all of these genes showed
down-regulation in BACHD and FVB brain as well as BALB/c
liver in animals treated with wig-1 ASO, as compared to control
samples. For example, PKCe which is highly expressed in both
mouse brain and liver was significantly reduced at both the RNA
and protein levels in BACHD and FVB brain, and in BALB/c
liver (p#0.1 and p#0.01 respectively) (Figure 6). Wig-1 ASO
treatment produced significant reductions in AUTS2 mRNA
levels in BACHD brain (p#0.01) (Figure 7). A trend in reduction
of AUTS2 mRNA level was observed in BALB/c liver (p#0.1)
whereas no reduction in AUTS2 levels was observed in non-
BACHD (FVB) mouse brain. Autism susceptibility candidate 2
(Auts2) is a gene associated with autism and mental retardation
[19,20] whose exact function is unknown, but is expressed in
different regions of the mouse brain.
Roundabout axon guidance receptor homolog 2 (ROBO2)
[21,22,23] is also expressed in brain and liver. Intrastriatal
injection of wig-1 ASO in BACHD and FVB mice resulted in
significant reductions of ROBO2 mRNA levels in both BACHD
and FVB striatum (p#0.05 and p#0.1 respectively) (Figure 7).
Furthermore, systemic administration of the wig-1 ASO also
resulted in marked reduction of ROBO2 mRNA levels in BALB/c
liver (p#0.1).
Another gene that was found to be down regulated in BACHD
brain and BALB/c liver (p#0.1 and p#0.05 respectedly) following
treatment with wig-1 ASO was the Pleckstrin homology domain
containing family A member 5 (PLEKHA5), which is expressed in
different tissues, with the highest level of expression in prefrontal
cortex, fetal brain, uterus, and adrenal gland (Figure 7). Further-
more, a statistically significant decrease in expression of the inner
mitochondrial membrane peptidase 2-like (IMMP2L) [24,25] gene
was also observed in BACHD (p#0.05) and FVB (p#0.01)
striatum following wig-1 ASO treatment, which has been linked to
a possible rare cause of Autism and Gilles de la Tourette syndrome
(GTS) [25]. Reductions in IMMP2L mRNA levels were also
Table 1. Genes down-regulated in BACHD mouse brain following wig-1 ASO treatment.
Down Regulated Genes Accession number Potential functions
zinc finger matrin type 3 (ZMAT3, wig-1) NM_009517.2 Cell cycle, DNA replication, Recombination, and repair,
cell cycle
autism susceptibility candidate 2 (AUTS2) NM_177047.3 Cell cycle, DNA replication, Recombination, and repair,
cell cycle
hemoglobin beta chain complex (HBB) XM_921422.1 Cell cycle, DNA replication, Recombination, and repair,
cell cycle
eukaryotic translation initiation factor 2C, 3 (EIF2C3) NM_153402.2 Cell cycle, DNA replication, Recombination, and repair,
cell cycle
integrin, beta-like 1 (ITGBL1) NM_145467.2 Cell cycle, DNA replication, Recombination, and repair,
cell cycle
potassium large conductance calcium-activated channel, subfamily
M, alpha member 1(KCNMA1)
NM_010610.2 Cell cycle, DNA replication, Recombination, and repair,
cell cycle
cyclin-dependent kinase 7 (CDK7) NM_009874.3 Cell cycle, DNA replication, Recombination, and repair,
cell cycle
protein kinase C, epsilon (PKCe) NM_011104.3 Psychological disorders, cell morphology, cellular
function and maintenance
amyloid beta (A4) precursor-like protein 2 (APLP2) NM_001102455.1 Psychological disorders, cell morphology, cellular
function and maintenance
latrophilin 3 (LPHN3) NM_198702.2 Psychological disorders, cell morphology, cellular
function and maintenance
polymerase (RNA) III (DNA directed) polypeptide H (POLR3H) NM_030229.4 Psychological disorders, cell morphology, cellular
function and maintenance
IMP2 inner mitochondrial membrane peptidase-like (S. cerevisiae) (IMMP2L) NM_053122.3 Psychological disorders, cell morphology, cellular
function and maintenance
roundabout homolog 2 (Drosophila) (ROBO2) NM_175549.4 Cellular movement, nervous system development and
function, cell-to-cell signaling and interaction
pleckstrin homology domain containing, family A member 5 (PLEKHA5) NM_144920.3 Cellular movement, nervous system development and
function, cell-to-cell signaling and interaction
glutamate receptor, ionotropic, delta 2 (GRID2) NM_008167.2 Cellular movement, nervous system development and
function, cell-to-cell signaling and interaction
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 (B3GALT1) NM_020283.3 Cellular movement, nervous system development and
function, cell-to-cell signaling and interaction
potassium voltage-gated channel, shaker-related subfamily,
member 2 (KCNA2)
NM_008417.4 Cellular movement, nervous system development and
function, cell-to-cell signaling and interaction
Ingenuity
TM Pathway Analysis was used to ascribe down-regulated genes with potential functions (additional genes can be found in Figure S2).
doi:10.1371/journal.pone.0029429.t001
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ASO (p#0.01) (Figure 7).
Glycoprotein transmembrane nmb (gpnmb) is expressed widely
in tissues including brain, liver, retina, skin, placenta, and salivary
gland. Following striatal wig-1 ASO treatment, a marked elevation
of gpnmb mRNA levels was observed in BACHD (p#0.1) and
FVB (p#0.05) striatum (Figure 8). Furthermore, elevations in
gpnmb mRNA levels were also observed in BALB/c liver
following systemic treatment with wig-1 ASO (p#0.1) (Figure 8).
Discussion
wig-1 is a regulatory protein that has been shown to function as
a transcription factor, an RNA binding protein, and a regulator of
both RNA and protein stabilization [1,4,9]. Furthermore, wig-1
has also been shown to have a complex relationship with the
tumor suppressor p53, with reports indicating that p53 can control
levels of wig-1 and that wig-1 can regulate levels of p53, suggesting
that p53 and wig-1 tightly control each other’s expression in
certain cell systems [9]. Moreover, p53 has been linked with
expression levels of the Huntington gene and with the Huntington
phenotype in mice [11,26]. Therefore, we investigated the effects
of wig-1 on p53 levels, on htt expression, and on gene expression
more broadly using microarray analysis in mouse brain and liver
using highly specific wig-1 antisense oligonucleotides (ASOs).
ASOs were administered to normal BALB/c mice systemically
and in BACHD and FVB mice by intrastriatal injection, and
effects on gene expression were examined. Since ASOs do not
cross the blood brain barrier [27,28] local administration is
required for ASO-mediated activity in the CNS. Direct ASO
administration to the striatum resulted in broad distribution with
strong uptake in both neuronal and glial cells, with the intensity of
ASO uptake being greatest in the proximity of the ASO injection
site. Moreover, marked reductions in wig-1 mRNA and protein
levels was demonstrated in the BACHD and FVB striatum and in
BALB/c liver, and this reduction in wig-1 levels was well tolerated
over a four week period.
wig-1 has been reported to bind to p53 mRNA in vitro, causing
stabilization of the p53 message [9]. Accordingly, siRNA-mediated
reduction in wig-1 levels resulted in a corresponding reduction in
p53 levels in cell culture [9]. However, in studies reported here,
suppression of wig-1 levels in mouse striatum or in mouse liver had
no significant effect on p53 mRNA or protein levels. The reason
behind this discrepancy is unclear, but most likely is related to
differences between the cell culture system and animals, or the
specific cell types examined. Certainly, cell culture may not be an
accurate representation of gene regulation in animals. Addition-
ally, the effects of wig-1 on p53 mRNA levels may differ between
different cell types, such as striatal cells (i.e., neuronal and glial
cells) and hepatocytes as described here relative to the osteosar-
coma cells and fibroblasts that were investigated in the prior
report. Interestingly, ASO-mediated suppression of endogenous
wig-1 levels in the striatum of BACHD mice led to a significant
reduction (approximately 50%) in mutant HTT protein levels with
no significant effect on the levels of endogenous wild type HTT
levels. The mechanisms underlying this result are not yet clear.
However, considering the fact that we have not seen significant
changes in mutant HTT mRNA levels despite reductions in
mutant protein levels suggests that wig-1 may be regulating mutant
HTT levels post-transcriptionally (data not shown). Nevertheless,
more studies are needed to establish the link between wig-1 and
mutant HTT protein expression.
Table 2. Genes up-regulated in BACHD mouse brain following wig-1 ASO treatment.
Up Regulated Genes Accession number Potential functions
B-cell leukemia/lymphoma 2 related protein A1a (BCL2A1) NM_009742.3 Genetic disorder, neurobiological disease, cell-to-cell
signaling and interaction
PYD and CARD domain containing (PYCARD) NM_023258.4 Genetic disorder, neurobiological disease, cell-to-cell
signaling and interaction
sterol O-acyltransferase 1 (SOAT1) NM_009230.3 Genetic disorder, neurobiological disease, cell-to-cell
signaling and interaction
caspase 8 (CASP8) NM_001080126.1 Cardiovascular disease, organismal injury and
abnormalities, inflammatory response
interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) NM_010501.2 Cardiovascular disease, organismal injury and
abnormalities, inflammatory response
apolipoprotein E (APOE) NM_009696.3 Cardiovascular disease, organismal injury and
abnormalities, inflammatory response
arachidonate 5-lipoxygenase activating protein (ALOX5AP) NM_009663.1 Neurobiology disease, endocrine system disorders,
metabolic disease
extracellular matrix protein 1(ECM1) NM_007899.2 Neurobiology disease, endocrine system disorders,
metabolic disease
intercellular adhesion molecule 1(ICAM1) NM_010493.2 Neurobiology disease, endocrine system disorders,
metabolic disease
glycoprotein (transmembrane) nmb (GPNMB, osteoactivin) NM_053110.4 Cancer, antigen presentation, cellular movement
N-acetylneuraminic acid synthase (sialic acid synthase) (NANS) NM_053179.3 Cancer, antigen presentation, cellular movement
asparaginase homolog (S. cerevisiae) (ASPG) NM_001081169.1 Cancer, antigen presentation, cellular movement
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 (ABCC3) NM_029600.3 Cell cycle, cellular development, gene expression
carnitine palmitoyltransferase 2 (CPT2) NM_009949.2 Cell cycle, cellular development, gene expression
transmembrane emp24 domain containing 3 (TMED3) NM_025360.2 Cell cycle, cellular development, gene expression
Ingenuity
TM Pathway Analysis was used to ascribe up-regulated genes with potential functions (additional genes can be found in Figure S3).
doi:10.1371/journal.pone.0029429.t002
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mouse liver and striatum following wig-1 suppression, broad
changes in mRNA levels was observed following wig-1 suppression
in mouse striatum based on microarray analysis. Our results
suggest that wig-1 can regulate gene expression through both gene
repression and activation, as reflected by both down-regulation
and up-regulation of genes following wig-1 ASO suppression. We
identified 204 genes that were up-regulated and 56 genes that were
down-regulated following wig-1 ASO treatment. These genes have
been linked to a broad range of putative cellular functions
including cell cycle regulation, DNA replication, cell survival, and
neurological function.
Wig-1 suppression promoted confirmed changes in two genes
linked to cancer. Wig-1 ASO treatment resulted in decreases in
PKCe levels in both mouse brain and liver. PKCe signaling is
involved in cell invasion, motility, proliferation, and survival, and
has been linked to malignancies of the central nervous system [29].
The role of PKCe in cancer promotion is believed in part to
involve the ras signaling pathway [30,31,32] and the regulation of
expression of specific Bcl-2 family members [33]. Wig-1
suppression also caused a significant upregulation in expression
of gpnmb in mouse brain and liver, a transmembrane glycoprotein
also known as osteoactivin or HGFIN. Gpnmb has been
implicated as a tumor suppressor, and has been reported to
promote cell transformation and proliferation, and loss of cell
contact dependency [34,35,36]. Furthermore, high expression of
gpnmb has been associated with aggressive melanoma, glioma and
breast cancer [37,38,39,40]. Interestingly, wig-1 has also been
reported to regulate tumor cell apoptosis and cell proliferation
[2,3]. Our findings suggest potential genes and mechanisms
relevant to cancer pathways that wig-1 may be acting through.
Our results also suggest a role for wig-1 in regulating gene
expression within specific pathways relevant to CNS function and
disease. Wig-1 suppression led to a reduction in expression of
numerous genes in mouse brain and liver. Genes down-regulated
and confirmed by RT-PCR included AUTS2, ROBO2, and
IMMP2L. AUTS2 (Autism susceptibility candidate 2) is a nuclear
protein that is highly expressed in developing neurons of certain
brain regions, notably the frontal cortex and cerebellum, and has
been linked with the neuropathy of autism [19,41]. ROBO2
(roundabout axon guidance receptor homolog 2) is a receptor for
SLIT1 ligand, which is critically important for axon guidance and
in CNS development [42,43,44]. IMMP2L (inner mitochondrial
membrane peptidase 2-like) is a mitochondrial peptidase believed
to be involved in polypeptide precursor processing within the inner
mitochondrial membrane and has been shown to be critical for
normal mitochondrial function through knockout mouse studies
(Lu et al.). Interestingly, the IMMP2L locus has been linked with
Autism Spectrum Disorders (ASDs) [24] and with Tourette
Syndrome [45,46,47]. Regulation of expression of both AUTS2
and IMMP2L by wig-1 suggests a possible role for wig-1 in autism.
The mechanism by which wig-1 regulates the expression of
genes shown to be modulated following wig-1 ASO treatment is
unknown. However, wig-1 has been shown to bind to the
Figure 6. Effects of wig-1 ASO treatment on PKCe levels. PKCe mRNA and protein levels in BACHD and FVB striatum, and BALB/c liver were
determined in animals treated with wig-1 ASO and compared to control animals. A) Effects of wig-1 ASO treatment on PKCe mRNA levels. B) Effects of
wig-1 ASO treatment on PKCe protein levels. Data are expressed as means 6 SEM (n=4;**p#0.05; ***p#0.01).
doi:10.1371/journal.pone.0029429.g006
Expression Analysis of wig-1 Antisense
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e29429promoter of some genes through its C2H2 zinc finger motifs and
thereby regulate transcription [1]. More recently, regulation of
RNA stability through binding of wig-1 to putative RNA sequence
motifs within the 39UTR of certain RNAs, including p53 [9], have
been proposed based on similarities between the wig-1 zinc finger
RNA binding motif and those of a small group of dsRNA-binding
proteins [5]. Interestingly, examination of the 39UTR of wig-1
regulated mRNAs identified in this study revealed the presence of
sequence motifs (e.g., UUAUUUAUU and AUUUAAUUUA)
that have been linked with RNA: protein binding and regulation
[48,49,50,51].
In summary, our studies indicate that wig-1 regulates gene
expression broadly in mouse brain and liver through mechanisms
that appear independent of p53. Our findings indicate that
reduction of wig-1 by $80% in adult mouse brain and liver are
generally well tolerated, and suggest that wig-1 can positively and
negatively regulate the expression of genes implicated in various
cellular pathways and pathologies including cancer and neurode-
Figure 7. Real Time-PCR confirmation of down-regulated mRNAs following wig-1 ASO treatment in mice. mRNA levels of Auts2, Robo2,
Plekha5, and IMMP2L in (A) BACHD striatum, (B) BALB/c liver, or (C) FVB striatum was compared to control animals. Data are expressed as means 6
SEM (n=4;*p#0.1;* * p#0.05; ***p#0.01).
doi:10.1371/journal.pone.0029429.g007
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posttranscriptional regulation of mutant huntingtin protein levels
may have been identified.
Materials and Methods
2
nd generation Antisense Oligonucleotides (ASOs)
chemistry
All oligonucleotides were 20 nucleotides in length and
chemically modified with phosphorothioate in the backbone and
29-O-methoxyethyl (MOE) on the wings with a central deoxy gap
(‘‘5-10-5’’ design). Oligonucleotides were synthesized using an
Applied Biosystems 380B automated DNA synthesizer (Perkin
Elmer-Applied Biosystems, Foster City, CA, USA) and purified. A
negative control oligonucleotide, which has the same chemical
composition as the wig-1 ASO but no complementarities to any
known gene sequence, was also included in the studies.
Identification and characterization of ISIS wig-1 ASOs in
vitro and in vivo
To identify mouse wig-1 antisense inhibitors, rapid-throughput
screens were performed in the bEND cell line (ATCC, CRL-
2299
TM). In brief, 80 ASOs were designed to the wig-1 mRNA
sequence, all of which targeted binding sites within the coding
region of the wig-1 mRNA. The reduction of target gene
expression was analyzed with real-time quantitative RT-PCR
after transfection of the cells with ASOs for 24 h. Based on target
reduction, 4 ASOs were selected and further characterized in a
dose-response screen. The most potent ASOs from the screen were
chosen, and their in vivo activity was confirmed by intraperitoneal
(IP) administration in BALB/c mice. The most potent ASO was
chosen as the wig-1 ASO for subsequent studies.
Animal studies
This study was conducted in accordance with the guidelines of
the Institutional Animal Care and Use Committee at Isis
Pharmaceuticals and approved by the committee. Protocol
number and PHS Assurance numbers are P-0190 and A4318-
01, respectively. Six-week-old male BALB/c mice were injected
with four wig-1 ASOs at 100 mg/kg/week or saline twice/week
for 4 weeks. ASOs were dissolved in PBS and administered
intraperitoneally. Animals were euthanized 48 hours after the last
dose. Blood, liver, kidney and spleen were collected to measure
toxicity, PK, as well as RNA and protein levels.
Treatment and surgery
Groups of four FVB (8 weeks of age) and BACHD mice (5-
months-old) were treated with wig-1 ASO at a dose of 25, 50, or
75 mg delivered by single striatal bolus injection. Control groups of
four FVB and BACHD mice were similarly treated with PBS or
with negative control oligonucleotide. Mice were individually
anaesthetized with 3% isoflurane and were maintained throughout
the surgical procedure in an ASI small animal stereotaxic system
(ASI Instruments, SAS-4100) with a gas nose cone delivering 2%
isoflurane. The scalp of the animal was sterilized with iodine
solution followed by 70% ethanol. Then, a longitudinal mid-
saggital incision 1 cm in length was made in the scalp. Hamilton
gas tight 10 mL Syringe with removable 26 gauge needle by
advancing the end of the needle through the scull to the
appropriate coordinate. Coordinates used: 0.5 mm anterior,
2.0 mm lateral on right and 3.0 mm deep from Bregma with flat
skull nosebar setting. Different concentrations of ASO in a total
volume of two ml/concentration were administered by injection.
Figure 8. Up-regulation of Gpnmb mRNA levels following wig-
1 ASO treatment. A) Gpnmb mRNA levels in BACHD striatum; B) FVB
striatum, and C) BALB/c liver. Data are expressed as means 6 SEM (n=4;
*p#0.1; **p#0.05).
doi:10.1371/journal.pone.0029429.g008
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using isoflurane followed by decapitation. Brain tissue, including
the striatum, was extracted for protein and RNA analysis.
Histopathology was conducted to assure the distribution of ASO
as well as safety.
Real-time quantitative PCR
RNA was extracted by using a QIAGEN RNAeasy kit
(QIAGEN). The mRNA was transcribed to cDNA by using
MuLV reverse transcriptase (New England Bio Labs). The
abundance of transcripts was assessed by real-time PCR on a
7700 Fast Real-Time PCR System (Applied Biosystems). Each run
was evaluated in triplicate for both the gene of interest and
endogenous control for mRNA levels, Cyclophilin A (Figure S1).
The expression data for the gene of interest were normalized for
the efficiency of amplification determined by the standard curve
included for each data acquisition.
Immunoblotting
For Western blots, samples were lysed in 500 mL of extraction
buffer [50 mM Tris (pH 8), 150 mM NaCl,1% NP-40, 0.5%
Sodium deoxycholate, 1 mM sodium orthovanadate, 1 mM NaF,
protease inhibitor cocktail set III, EDTA-free (539134; EMD
CHEMICALS, INC.)]. The homogenate was centrifuged at
14,0006 g for 10 min at 4uC to pellet insoluble material. The
supernatant was saved as the final lysate and stored at 280uC.
Fifty micrograms of lysate were electrophoresed through 4–20%
(for wig-1 protein) or 12% (for p53 protein) Tris-Glycine gel and
transferred to nitrocellulose membrane (iBlot, Invitrogen). The
membrane was blocked in 5% milk for one hour and then
incubated with either a-rabbit ZMAT3 (ARP50793_P050, Aiva
Systems Biology), a-mouse p53, 1C12 (2524, Cell Signaling), a-
rabbit PKCe, 22B10 (2683, Cell Signaling), anti-mouse huntingtin
(MAB2166, Millipore) or a-mouse a-tubulin, DM1A (ab7291,
Abcam) overnight. The membrane was washed extensively and
then incubated with either anti-rabbit IgG or anti-mouse IgG (GE
healthcare UK limited). Chemiluminescence detection reagents
(ECL Plus; Amersham Pharmacia) enabled visualization of
peroxidase reaction products, and quantified using the software
ImageJ.
Immunohistochemistry
For hemotoxylin and eosin (H & E) staining, pieces of liver from
BALB/c mice were fixed in 10% buffered formalin and embedded
in paraffin wax. Brain sections were also fixed in 10% formalin.
Multiple adjacent 4-mm sections were cut and mounted on glass
slides. After dehydration, the sections were stained. Images of the
histological sections were analyzed.
Microarray gene expression analysis
Total RNA was extracted from BACHD striatum, treated with
wig-1 ASO, negative control ASO, or PBS, using RNeasy Plus
mini kits (Qiagen). Gene expression was analyzed by hybridization
to the MouseWG-6 v2 Expression BeadChip array (Illumina), and
array data analysis was performed using Bioconductor packages
lumi and siggenes [52]. The entire microarray data set has been
submitted to GEO [53] and can be referenced via accession ID
GSE29751. Siggenes was used to determine probes showing
statistically significant differential expression at an FDR (False
Discovery Rate) cutoff of 0.100. Gene network prediction was
determined by using Ingenuity
TM Pathway Analysis (IPA)
(Ingenuity Systems, CA, USA).
Supporting Information
Figure S1 List of primers used for real-time PCR.
(DOCX)
Figure S2 Gene network pathways identified by Inege-
nuity Pathway Analysis for down-regulated genes. The
table above identifies the genes within a network and includes a
score, which is used to rank the networks. The genes within each
network are comprised of genes identified by microarray analysis
in addition to other genes within the network as identified by
Ingenuity Pathway Analysis. The total number of genes identified
as down-regulated via microarray analysis within each network is
identified in the column labeled ‘‘Focus Molecules’’. The score for
each network is obtained from the 2log10(p-value), where the p-
value is obtained from a Fisher Exact Test. The score ranks the
networks based on the probability of obtaining the same networks
by chance when sampling a similar number of genes from the
Ingenuity Knowledge Base. Network scores with a high value
(.=2) are more significant.
(DOCX)
Figure S3 Gene network pathways identified by Inege-
nuity Pathway Analysis for up-regulated genes. The table
above identifies the genes within a network and includes a score,
which is used to rank the networks. The genes within each network
are comprised of genes identified by microarray analysis in
addition to other genes within the network as identified by
Ingenuity Pathway Analysis. The total number of genes identified
as up-regulated via microarray analysis within each network is
identified in the column labeled ‘‘Focus Molecules’’. The score for
each network is obtained from the 2log10(p-value), where the p-
value is obtained from a Fisher Exact Test. The score ranks the
networks based on the probability of obtaining the same networks
by chance when sampling a similar number of genes from the
Ingenuity Knowledge Base. Network scores with a high value
(.=2) are more significant.
(DOCX)
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